ICI 213689: a meropenem metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10340993 |
| MeSH ID | M0189712 |
| Synonym |
|---|
| uk 1a |
| unii-9h9wbh911y |
| zm 213689 |
| 9h9wbh911y , |
| zm 213,689 |
| 2h-pyrrole-2-acetic acid, 5-carboxy-4-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-3,4-dihydro-alpha-(1-hydroxyethyl)-3-methyl-, (2s-(2alpha(r*),3alpha,4beta(3r*,5r*)))- |
| 2h-pyrrole-2-acetic acid, 5-carboxy-4-(((3s,5s)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-3,4-dihydro-alpha-(1-hydroxyethyl)-3-methyl-, (alphas,2s,3r,4s)- |
| 2h-pyrrole-2-acetic acid, 5-carboxy-4-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-3,4-dihydro-alpha-(1-hydroxyethyl)-3-methyl- |
| ici-213,689 |
| ici 213689 |
| h 4295 |
| 124190-28-9 |
| h-4295 |
| 2h-pyrrole-2-acetic acid, 5-carboxy-4-(((3s,5s)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-3,4-dihydro-.alpha.-((1r)-hydroxyethyl)-3-methyl-, (.alpha.s,2s,3r,4s)- |
| uk-1a |
| zm-213689 |
| ici-213689 |
| (2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-bis(oxidanyl)-1-oxidanylidene-butan-2-yl]-4-[(3~{s},5~{s})-5-(dimethylcarbamoy |
| l)pyrrolidin-3-yl]sulfanyl-3-methyl-3,4-dihydro-2~{h}-pyrrole-5-carboxylic acid |
| Q27272567 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters of unchanged meropenem were determined by using the HPLC data." | ( Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Borsa-Lebas, F; Etienne, I; Fillastre, JP; Humbert, G; Leroy, A, 1992) | 0.28 |
| " No statistically significant differences were found between the first dose and steady state or between groups for any plasma pharmacokinetic parameters-including the highest observed plasma concentrations, plasma concentrations at 6 hours after dosing (C6h), terminal half-life, area under the plasma concentration-time curve (AUC), area under the first moment of the curve, plasma clearance, steady-state volume of distribution, and accumulation ratios-on the basis of either AUC or C6h." | ( Pharmacokinetics of meropenem in patients with liver disease. Birmingham, B; Lasseter, K; Thyrum, PT; Yeh, C, 1997) | 0.3 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dosage adjustments of meropenem will be necessary in patients with severe renal impairment." | ( Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Borsa-Lebas, F; Etienne, I; Fillastre, JP; Humbert, G; Leroy, A, 1992) | 0.28 |
| " The dosing interval of meropenem should be prolonged in a regular proportion to the decline in CLCR (12 h in group II patients and 24 h in group III patients)." | ( Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Chimata, M; Kakuta, S; Nagase, M; Shimomura, M; Suzuki, Y, 1993) | 0.29 |
| " No statistically significant differences were found between the first dose and steady state or between groups for any plasma pharmacokinetic parameters-including the highest observed plasma concentrations, plasma concentrations at 6 hours after dosing (C6h), terminal half-life, area under the plasma concentration-time curve (AUC), area under the first moment of the curve, plasma clearance, steady-state volume of distribution, and accumulation ratios-on the basis of either AUC or C6h." | ( Pharmacokinetics of meropenem in patients with liver disease. Birmingham, B; Lasseter, K; Thyrum, PT; Yeh, C, 1997) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||